Could IVO-21 Lead to a New ME/CFS Mitochondrial Treatment?
In May 2026, Solve selected Dr. Jay H. Chung (National Institutes of Health) as a recipient of our latest ME/CFS Catalyst Award.
Dr. Chung’s groundbreaking study, “Mitochondrial Stabilizer IVO-21 As Therapy for ME/CFS,” is focused on developing a new way to restore cellular energy production by targeting two of the most debilitating and poorly treated aspects of ME/CFS and Long Covid—mitochondrial dysfunction and chronic inflammation—mechanisms believed to drive symptoms such as fatigue and brain fog.
The compound at the heart of this study is IVO, an inexpensive small-molecule therapy that can be easily taken as pills. Early results in cell-culture models suggest IVO restores mitochondrial energy production and reduces systemic inflammation. The next step is to evaluate how well IVO alleviates sickness behavior in preclinical (mouse) models.
In this free educational webinar hosted by Solve Vice President of Scientific Programs Dr. Jessica Maya, Dr. Chung explains why his research is an essential step toward future clinical studies that could benefit millions and how it could pave the way for a safe, accessible treatment that addresses the root causes of these complex diseases.
Watch the recording below or here. View the webinar presentation deck here.